294 related articles for article (PubMed ID: 35713127)
1. Surface Engineered Dendrimers: A Potential Nanocarrier for the Effective Management of Glioblastoma Multiforme.
Sahoo RK; Gupta T; Batheja S; Goyal AK; Gupta U
Curr Drug Metab; 2022; 23(9):708-722. PubMed ID: 35713127
[TBL] [Abstract][Full Text] [Related]
2. Overcoming the blood-brain tumor barrier for effective glioblastoma treatment.
van Tellingen O; Yetkin-Arik B; de Gooijer MC; Wesseling P; Wurdinger T; de Vries HE
Drug Resist Updat; 2015 Mar; 19():1-12. PubMed ID: 25791797
[TBL] [Abstract][Full Text] [Related]
3. Potential of Nanocarrier-Associated Approaches for Better Therapeutic Intervention in the Management of Glioblastoma.
Vikram ; Kumar S; Ali J; Baboota S
Assay Drug Dev Technol; 2024; 22(2):73-85. PubMed ID: 38193798
[No Abstract] [Full Text] [Related]
4. Targeting brain tumors with innovative nanocarriers: bridging the gap through the blood-brain barrier.
Wadhwa K; Chauhan P; Kumar S; Pahwa R; Verma R; Goyal R; Singh G; Sharma A; Rao N; Kaushik D
Oncol Res; 2024; 32(5):877-897. PubMed ID: 38686045
[TBL] [Abstract][Full Text] [Related]
5. Recent Advances in the Use of Lipid-Based Nanoparticles Against Glioblastoma Multiforme.
Ortega-Berlanga B; Gonzalez C; Navarro-Tovar G
Arch Immunol Ther Exp (Warsz); 2021 Mar; 69(1):8. PubMed ID: 33772646
[TBL] [Abstract][Full Text] [Related]
6. Amphetamine decorated cationic lipid nanoparticles cross the blood-brain barrier: therapeutic promise for combating glioblastoma.
Saha S; Yakati V; Shankar G; Jaggarapu MMCS; Moku G; Madhusudana K; Banerjee R; Ramkrishna S; Srinivas R; Chaudhuri A
J Mater Chem B; 2020 May; 8(19):4318-4330. PubMed ID: 32330214
[TBL] [Abstract][Full Text] [Related]
7. Design of multifunctional peptide collaborated and docetaxel loaded lipid nanoparticles for antiglioma therapy.
Kadari A; Pooja D; Gora RH; Gudem S; Kolapalli VRM; Kulhari H; Sistla R
Eur J Pharm Biopharm; 2018 Nov; 132():168-179. PubMed ID: 30244167
[TBL] [Abstract][Full Text] [Related]
8. Glioblastoma multiforme: a glance at advanced therapies based on nanotechnology.
Rezaei V; Rabiee A; Khademi F
J Chemother; 2020 May; 32(3):107-117. PubMed ID: 31984871
[TBL] [Abstract][Full Text] [Related]
9. CREKA peptide-conjugated dendrimer nanoparticles for glioblastoma multiforme delivery.
Zhao J; Zhang B; Shen S; Chen J; Zhang Q; Jiang X; Pang Z
J Colloid Interface Sci; 2015 Jul; 450():396-403. PubMed ID: 25863222
[TBL] [Abstract][Full Text] [Related]
10. 'Dendrimer-Cationized-Albumin' encrusted polymeric nanoparticle improves BBB penetration and anticancer activity of doxorubicin.
Muniswamy VJ; Raval N; Gondaliya P; Tambe V; Kalia K; Tekade RK
Int J Pharm; 2019 Jan; 555():77-99. PubMed ID: 30448308
[TBL] [Abstract][Full Text] [Related]
11. The Effect of Biotinylated PAMAM G3 Dendrimers Conjugated with COX-2 Inhibitor (celecoxib) and PPARγ Agonist (Fmoc-L-Leucine) on Human Normal Fibroblasts, Immortalized Keratinocytes and Glioma Cells in Vitro.
Uram Ł; Misiorek M; Pichla M; Filipowicz-Rachwał A; Markowicz J; Wołowiec S; Wałajtys-Rode E
Molecules; 2019 Oct; 24(20):. PubMed ID: 31652556
[TBL] [Abstract][Full Text] [Related]
12. Nose-to-brain drug delivery for the treatment of glioblastoma multiforme: nanotechnological interventions.
Kumar N; Khurana B; Arora D
Pharm Dev Technol; 2023 Dec; 28(10):1032-1047. PubMed ID: 37975846
[TBL] [Abstract][Full Text] [Related]
13. Resveratrol targeting of AKT and p53 in glioblastoma and glioblastoma stem-like cells to suppress growth and infiltration.
Clark PA; Bhattacharya S; Elmayan A; Darjatmoko SR; Thuro BA; Yan MB; van Ginkel PR; Polans AS; Kuo JS
J Neurosurg; 2017 May; 126(5):1448-1460. PubMed ID: 27419830
[TBL] [Abstract][Full Text] [Related]
14. Recent Advances on Glioblastoma Multiforme and Nano-drug Carriers: A Review.
Liao W; Fan S; Zheng Y; Liao S; Xiong Y; Li Y; Liu J
Curr Med Chem; 2019; 26(31):5862-5874. PubMed ID: 29768997
[TBL] [Abstract][Full Text] [Related]
15. A novel doxorubicin loaded folic acid conjugated PAMAM modified with borneol, a nature dual-functional product of reducing PAMAM toxicity and boosting BBB penetration.
Xu X; Li J; Han S; Tao C; Fang L; Sun Y; Zhu J; Liang Z; Li F
Eur J Pharm Sci; 2016 Jun; 88():178-90. PubMed ID: 26965003
[TBL] [Abstract][Full Text] [Related]
16. Inducing a Transient Increase in Blood-Brain Barrier Permeability for Improved Liposomal Drug Therapy of Glioblastoma Multiforme.
Lundy DJ; Lee KJ; Peng IC; Hsu CH; Lin JH; Chen KH; Tien YW; Hsieh PCH
ACS Nano; 2019 Jan; 13(1):97-113. PubMed ID: 30532951
[TBL] [Abstract][Full Text] [Related]
17. Temozolomide nano enabled medicine: promises made by the nanocarriers in glioblastoma therapy.
Yasaswi PS; Shetty K; Yadav KS
J Control Release; 2021 Aug; 336():549-571. PubMed ID: 34229001
[TBL] [Abstract][Full Text] [Related]
18. Chitosan Engineered PAMAM Dendrimers as Nanoconstructs for the Enhanced Anti-Cancer Potential and Improved In vivo Brain Pharmacokinetics of Temozolomide.
Sharma AK; Gupta L; Sahu H; Qayum A; Singh SK; Nakhate KT; Ajazuddin ; Gupta U
Pharm Res; 2018 Jan; 35(1):9. PubMed ID: 29294212
[TBL] [Abstract][Full Text] [Related]
19. Nanocarriers for the treatment of glioblastoma multiforme: Current state-of-the-art.
Karim R; Palazzo C; Evrard B; Piel G
J Control Release; 2016 Apr; 227():23-37. PubMed ID: 26892752
[TBL] [Abstract][Full Text] [Related]
20. PAMAM Dendrimer Nanomolecules Utilized as Drug Delivery Systems for Potential Treatment of Glioblastoma: A Systematic Review.
Fana M; Gallien J; Srinageshwar B; Dunbar GL; Rossignol J
Int J Nanomedicine; 2020; 15():2789-2808. PubMed ID: 32368055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
